Results 31 to 40 of about 1,991 (194)

Mavacamten: First Approval

Drugs, 2022
Mavacamten (Camzyos™) is an oral small-molecule cardiac myosin inhibitor developed by MyoKardia, Inc., a wholly owned subsidiary of Bristol Myers Squibb, for the treatment of hypertrophic cardiomyopathy (HCM) and diseases of diastolic dysfunction. In April 2022, mavacamten was approved for use in the USA in the treatment of adults with symptomatic New ...
openaire   +2 more sources

Mavacamten, uma nova terapia revolucionária na HOCM: uma revisão de literatura [PDF]

, 2021
A miocardiopatia hipertrófica (MCH) é uma das doenças cardíacas genéticas mais frequentes, sendo definida por um espessamento da parede ventricular esquerda ≥15 mm, na ausência de outras causas de sobrecarga ventricular.
Tiago Filipe Sá Lopes Ribeiro Aguiar
core  

Patient-Level Artificial Intelligence–Enhanced Electrocardiography in Hypertrophic Cardiomyopathy Longitudinal Treatment and Clinical Biomarker Correlations [PDF]

, 2023
BackgroundArtificial intelligence (AI) applied to 12-lead electrocardiographs (ECGs) can detect hypertrophic cardiomyopathy (HCM).ObjectivesThe purpose of this study was to determine if AI-enhanced ECG (AI-ECG) can track longitudinal therapeutic response
Abraham, Theodore P, Abreau, Sean, Agarwal, Priyanka, Attia, Zachi I, Balasubramanyam, Aarthi, Barrios, Joshua P, Dewland, Thomas A, Edelberg, Jay M, Friedman, Paul A, Lester, Steven J, Li, Yunfan, Masri, Ahmad, Noseworthy, Peter A, Olgin, Jeffrey E, Sehnert, Amy J, Siontis, Konstantinos C, Tison, Geoffrey H, Wang, Andrew   +17 more
core   +1 more source

Efficacy and safety of mavacamten in treatment of hypertrophic cardiomyopathy: a systematic review and meta-analysis

Future Science OA, 2023
Aim: This meta-analysis was performed to assess the efficacy and safety of mavacamten in patients with hypertrophic cardiomyopathy. Methods & materials: A search was conducted using PubMed, Cochrane, and Scopus up to August 2022 for randomized studies ...
Areeba Memon, Muhammad Omar Larik, Zoha Khan, Maryam Urooj, Areeka Irfan, Beena Kumari, Mehak Faisal, Rida Siddiqui, Moniba Tehrim, Ishaque Hameed   +9 more
doaj   +1 more source

Effects of omecamtiv mecarbil and mavacamten in isolated human atrium [PDF]

, 2023
Heart failure is a syndrome that can result from impaired heart muscle contractions like in dilative cardiomyopathy but also from hypertrophic obstructive cardiomyopathy (HOCOM).
Abella, Lina Maria Rayo, Gergs, Ulrich, Hofmann, Britt, Höhm, Christian, Neumann, Joachim   +4 more
core   +1 more source

Mavacamten in Obstructive Hypertrophic Cardiomyopathy: National Insights on Access and Safety Profile From Real‐World Data

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background Mavacamten improves symptoms in obstructive hypertrophic cardiomyopathy, but real‐world prescription patterns, safety profile, and the effect of atrial fibrillation (AF) on outcomes remain unclear. Methods An observational multicenter analysis
Ayman R. Fath, Amro Aglan, Srihari S. Naidu, Michael J. Mader, Robert J. Chilton, Islam Y. Elgendy, Martin S. Maron, Ethan J. Rowin   +7 more
doaj   +1 more source

Long-term effect of mavacamten in obstructive hypertrophic cardiomyopathy. [PDF]

BACKGROUND AND AIMS: Long-term safety and efficacy of mavacamten in patients with obstructive hypertrophic cardiomyopathy (HCM) are unknown. MAVA-LTE (NCT03723655) is an ongoing, 5-year, open-label extension study designed to evaluate the long-term ...
Abraham, Theodore, Balaratnam, Ganesh, Barriales-Villa, Roberto, Choudhury, Lubna, Fox, Shawna, Garcia-Pavia, Pablo, Hagege, Albert, Hegde, Sheila, Jensen, Morten, Lakdawala, Neal, Masri, Ahmad, Olivotto, Iacopo, Oręziak, Artur, Owens, Anjali, Seidler, Tim, Shah, Ashish, Wang, Andrew, Wheeler, Matthew, Wojakowski, Wojciech   +18 more
core   +2 more sources

Considerations for drug trials in hypertrophic cardiomyopathy

ESC Heart Failure, Volume 12, Issue 2, Page 1095-1112, April 2025.
Abstract Hypertrophic cardiomyopathy (HCM) is a heterogeneous condition with potentially serious manifestations. Management has traditionally comprised therapies to palliate symptoms and implantable cardioverter‐defibrillators to prevent sudden cardiac death. The need for disease‐modifying therapies has been recognized for decades.
John P. Farrant, Matthias Schmitt, Anna B. Reid, Clifford J. Garratt, William G. Newman, Aneil Malhotra, Rhys Beynon, Masliza Mahmod, Betty Raman, Robert M. Cooper, Dana Dawson, Thomas Green, Sanjay K. Prasad, Anvesha Singh, Susanna Dodd, Hugh Watkins, Stefan Neubauer, Christopher A. Miller   +17 more
wiley   +1 more source

Pharmacokinetics and safety of mavacamten in healthy Chinese participants with different CYP2C19 phenotypes

Clinical and Translational Science
Obstructive hypertrophic cardiomyopathy (oHCM) is a subtype of HCM characterized by left ventricular outflow tract obstruction resulting from cardiac muscle hypertrophy and anatomic alterations in the mitral valve and apparatus.
Xiaojie Wu, Nanye Chen, Peiwen Hsu, Jing Sun, Wenting Li, Qi Wang, Merali Samira, Qiong Wei, Jicheng Yu, Guoying Cao, Haijing Yang, Lili Wang, Jingjing Wang, Yi Jin, Wei Liu, Jufang Wu, Jinjie He, Cheng Lyu, Jing Zhang   +18 more
doaj   +1 more source

Human engineered cardiac tissue model of hypertrophic cardiomyopathy recapitulates key hallmarks of the disease and the effect of chronic mavacamten treatment

Frontiers in Bioengineering and Biotechnology, 2023
Introduction: The development of patient-specific induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) offers an opportunity to study genotype-phenotype correlation of hypertrophic cardiomyopathy (HCM), one of the most common inherited cardiac
Kai Wang, Brian J. Schriver, Roozbeh Aschar-Sobbi, Alex Y. Yi, Nicole T. Feric, Michael P. Graziano   +5 more
doaj   +1 more source